{"id":65031,"date":"2026-05-12T13:59:25","date_gmt":"2026-05-12T05:59:25","guid":{"rendered":"https:\/\/flcube.com\/?p=65031"},"modified":"2026-05-12T13:59:26","modified_gmt":"2026-05-12T05:59:26","slug":"beijing-sun-novo-partners-with-chinese-academy-of-medical-sciences-on-category-1-antibacterial-drug-imb0304","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65031","title":{"rendered":"Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304"},"content":{"rendered":"\n<p><strong>Beijing Sun-Novo Pharmaceutical Research Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688621:SHA\">SHA: 688621<\/a>) announced a strategic research and development partnership with the <strong>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (IMB)<\/strong> for <strong>IMB0304<\/strong>, a <strong>Category 1 antibacterial drug<\/strong> candidate designed to address urgent unmet needs in infectious disease treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-framework\">Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Beijing Sun-Novo Pharmaceutical Research Co., Ltd. and Institute of Medicinal Biotechnology (IMB), CAMS<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>IMB0304 \u2013 Category 1 novel antibacterial drug<\/td><\/tr><tr><td><strong>Collaboration Scope<\/strong><\/td><td>Joint research and development through clinical advancement<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Leverage complementary strengths to accelerate development timeline<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical\/early development (specific phase not disclosed)<\/td><\/tr><tr><td><strong>Regulatory Classification<\/strong><\/td><td>Category 1 (innovative drug with new chemical entity status in China)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-innovation\">Product Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class:<\/strong> Novel antibacterial agent (mechanism of action undisclosed)<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> Category 1 classification indicates new chemical entity with no approved equivalents in China<\/li>\n\n\n\n<li><strong>Development Strategy:<\/strong> Combined expertise from academic research institution (IMB) and commercial pharmaceutical company (Sun-Novo)<\/li>\n\n\n\n<li><strong>Therapeutic Focus:<\/strong> Addresses critical gaps in antibacterial therapy, potentially targeting drug-resistant pathogens<\/li>\n\n\n\n<li><strong>Innovation Potential:<\/strong> Represents China&#8217;s push toward domestic innovation in anti-infective therapeutics amid global antimicrobial resistance crisis<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Antibacterial Pipeline Gap<\/strong><\/td><td>Limited novel antibiotic development globally due to commercial challenges; public-private partnerships essential<\/td><\/tr><tr><td><strong>China&#8217;s Innovation Push<\/strong><\/td><td>Aligns with national strategy to develop domestically-owned innovative medicines for critical therapeutic areas<\/td><\/tr><tr><td><strong>Academic-Industry Model<\/strong><\/td><td>Combines IMB&#8217;s research expertise with Sun-Novo&#8217;s drug development and regulatory capabilities<\/td><\/tr><tr><td><strong>Public Health Impact<\/strong><\/td><td>Potential to address rising antimicrobial resistance (AMR) threats in China and globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The collaboration exemplifies China&#8217;s evolving biopharmaceutical innovation ecosystem, where academic institutions and commercial entities increasingly partner to advance novel therapeutics through the challenging antibacterial development pathway.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antibacterial Market Dynamics:<\/strong> Despite clinical need, antibiotic development faces reimbursement and commercialization challenges; partnership mitigates development risk<\/li>\n\n\n\n<li><strong>Regulatory Incentives:<\/strong> Category 1 drugs in China receive priority review, accelerated approval pathways, and extended market exclusivity<\/li>\n\n\n\n<li><strong>Global Opportunity:<\/strong> Successful candidates may address worldwide AMR crisis, with potential for international partnerships and regulatory filings<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Success would validate Sun-Novo&#8217;s strategy of partnering with premier research institutions for early-stage innovation<\/li>\n\n\n\n<li><strong>Investment Implications:<\/strong> Demonstrates commitment to high-value innovative assets beyond generic\/biosimilar portfolio<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership arrangements, development timelines, and commercial expectations for IMB0304. Actual results may differ due to risks including preclinical\/clinical outcomes, regulatory decisions, funding availability, and competitive dynamics in the antibacterial therapeutic area.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced a strategic research and development partnership&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65032,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1262,2604],"class_list":["post-65031","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-sha-688621","tag-sun-novo-pharmaceutical-research"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced a strategic research and development partnership with the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (IMB) for IMB0304, a Category 1 antibacterial drug candidate designed to address urgent unmet needs in infectious disease treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65031\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304\" \/>\n<meta property=\"og:description\" content=\"Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced a strategic research and development partnership with the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (IMB) for IMB0304, a Category 1 antibacterial drug candidate designed to address urgent unmet needs in infectious disease treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65031\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T05:59:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-12T05:59:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1201.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65031#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65031\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304\",\"datePublished\":\"2026-05-12T05:59:25+00:00\",\"dateModified\":\"2026-05-12T05:59:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65031\"},\"wordCount\":411,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65031#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1201.webp\",\"keywords\":[\"SHA: 688621\",\"Sun-Novo Pharmaceutical Research\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65031#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65031\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65031\",\"name\":\"Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65031#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65031#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1201.webp\",\"datePublished\":\"2026-05-12T05:59:25+00:00\",\"dateModified\":\"2026-05-12T05:59:26+00:00\",\"description\":\"Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced a strategic research and development partnership with the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (IMB) for IMB0304, a Category 1 antibacterial drug candidate designed to address urgent unmet needs in infectious disease treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65031#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65031\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65031#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1201.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1201.webp\",\"width\":1080,\"height\":608,\"caption\":\"Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65031#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304 - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced a strategic research and development partnership with the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (IMB) for IMB0304, a Category 1 antibacterial drug candidate designed to address urgent unmet needs in infectious disease treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65031","og_locale":"en_US","og_type":"article","og_title":"Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304","og_description":"Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced a strategic research and development partnership with the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (IMB) for IMB0304, a Category 1 antibacterial drug candidate designed to address urgent unmet needs in infectious disease treatment.","og_url":"https:\/\/flcube.com\/?p=65031","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-12T05:59:25+00:00","article_modified_time":"2026-05-12T05:59:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1201.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65031#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65031"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304","datePublished":"2026-05-12T05:59:25+00:00","dateModified":"2026-05-12T05:59:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65031"},"wordCount":411,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65031#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1201.webp","keywords":["SHA: 688621","Sun-Novo Pharmaceutical Research"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65031#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65031","url":"https:\/\/flcube.com\/?p=65031","name":"Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65031#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65031#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1201.webp","datePublished":"2026-05-12T05:59:25+00:00","dateModified":"2026-05-12T05:59:26+00:00","description":"Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced a strategic research and development partnership with the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (IMB) for IMB0304, a Category 1 antibacterial drug candidate designed to address urgent unmet needs in infectious disease treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65031#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65031"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65031#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1201.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1201.webp","width":1080,"height":608,"caption":"Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65031#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1201.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65031"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65031\/revisions"}],"predecessor-version":[{"id":65033,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65031\/revisions\/65033"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65032"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}